NOT FOR USE WITHOUT PERMISSION. ©2022 American Heart Association

FORM SELECTION		Legend: Elements in bold are required								
Heart Failure	Pat	ient ID:								
DEMOGRAPHICS TAB										
Demographics										
Sex	O Male O Female O Unk	nown								
Patient Gender Identity	<ul> <li>Male</li> <li>Female</li> <li>Female-to-Male (FTM)/Transgender Male/Trans Man</li> <li>Male-to-Female (MTF)/Transgender Female/Trans Woman</li> <li>Genderqueer, neither exclusively male nor female</li> <li>Additional gender category or other</li></ul>									
Patient-Identified Sexual Orientation	<ul> <li>Straight or heterosexual</li> <li>Lesbian or gay</li> <li>Queer, pansexual, and/or questioning</li> <li>Something else; please specify.</li> <li>Don't know</li> <li>Declined to answer</li> </ul>									
Date of Birth	//(MM/DD/YYYY) F	Patient Postal Code								
Payment Source	<ul> <li>Medicare Title 18</li> <li>Medicaid Title 19</li> <li>Medicaid – Private/HMO/PPO/Other</li> <li>Medicaid – Private/HMO/PPO/Other</li> <li>Private/HMO/PPO/Other</li> <li>VA/CHAMPVA/Tricare</li> <li>Self-pay/No Insurance</li> <li>Other/Not Documented/UTD</li> </ul>									
External Tracking ID										
Race and Ethnicity										
Race	<ul> <li>American Indian or Alaska Native</li> <li>Asian</li> <li>Asian Indian</li> <li>Chinese</li> <li>Filipino</li> <li>Japanese</li> <li>Korean</li> <li>Vietnamese</li> <li>Other Asian</li> </ul>	<ul> <li>Black or African American</li> <li>Native Hawaiian or Pacific Islander</li> <li>Native Hawaiian</li> <li>Guamanian or Chamorro</li> <li>Samoan</li> <li>Other Pacific Islander</li> <li>White</li> <li>UTD</li> </ul>								
Hispanic Ethnicity	O Yes	O No/UTD								
Select Hispanic Origin Group(s):	<ul> <li>Mexican, Mexican American, Chi</li> <li>Cuban</li> <li>Puerto Rican</li> <li>Another Hispanic, Latino, or Spail</li> </ul>	cano/a								
ADMISSIONS TAB										
Arrival and Admission										
Internal Tracking ID	Physician/	/Provider NPI								
Arrival Date/Time	//: Admissio	on Date//								
Transferred in (from another ED?)	O Yes	O No								
Point of Origin for Admission or Visit	<ul> <li>O 1. Non-Healthcare Facility Point of Origin</li> <li>O 2. Clinic</li> </ul>	<ul> <li>O 6. Transfer from another Health Care Facility</li> <li>O 7. Emergency Room</li> <li>O 9. Information not available</li> </ul>								

NOT FOR USE WITHOUT PERMISSIO	N. ©2022 American Heart As	sociation	December 2022					
	<ul> <li>4. Transfer from a Ho (Different Facility)</li> <li>5. Transfer from a Sk Nursing Facility (SNF Intermediate Care Facility)</li> </ul>		<ul> <li>F. Transfer from Hospice and is Under a Hospice Plan of Care or Enrolled in a Hospice Program</li> </ul>					
Discharge Date/Time	'!::		4					
Medical History								
Medical History (Select all t	hat apply):							
<ul> <li>Anemia</li> <li>Atrial Fib (chronic or recuil</li> <li>Atrial Flutter (chronic or recuil</li> <li>Atrial Flutter (chronic or recuil</li> <li>ATTR-CM         <ul> <li>Hereditary</li> <li>Wild-type</li> </ul> </li> <li>CAD</li> <li>CardioMEMs (implantable</li> <li>COPD or Asthma</li> <li>CRT-D (cardiac resynchronic)</li> <li>CRT-P (cardiac resynchronic)</li> <li>Diabetes</li> <li>Dialysis (chronic)</li> <li>Emerging Infectious Diserversion</li> <li>SARS-COV-1</li> <li>SARS-COV-2 (COVII</li> <li>Other infectious res</li> </ul>		Heart failure Heart Transplant Hyperlipidemia Hypertension ICD only Kidney Transplant Left Ventricular Assist Device Pacemaker Peripheral Vascular Disease Prior CABG Prior MI Prior PCI Renal insufficiency - chronic (SCr>2.0) Sleep-Disordered Breathing TAVR TMVR Tricuspid Valve procedure Valvular Heart Disease Ventricular assist device						
Diabetes Type:	O Type 1	O Type 2	0	ND				
Diabetes Duration:	<ul> <li>Q &lt;5 years</li> <li>Q 5 - &lt;10 years</li> <li>Q 10 - &lt;20 years</li> <li>Q &gt;=20 years</li> <li>Q Unknown</li> </ul>							
Sleep-Disordered Breathing Type:	<ul> <li>Obstructive</li> <li>Central</li> <li>Mixed</li> <li>Unknown/Not Doc</li> </ul>	cumented						
Equipment used at home:	<ul> <li>O2</li> <li>CPAP</li> <li>BiPAP</li> <li>Adaptive Servo-V</li> <li>None</li> <li>Unknown/Not Doc</li> </ul>	cumented						
History of cigarette smoking				O Yes	0	No		
History of vaping or e-cigarett				O Yes	0	No/ND		
Heart Failure History Etiology: Check if history of:		Ischemic/(	CAD	<ul> <li>Non-Ischemic</li> <li>Alcohol/Oth</li> <li>Chemothera</li> <li>Familial</li> <li>Hypertensiv</li> <li>Postpartum</li> </ul>	apy /e			

### NOT FOR USE WITHOUT PERMISSION. ©2022 American Heart Association

NOT FOR USE WITHOUT PERMISSION. ©2022 American He	art Association			D	ecember 2022	
				l er Etiology nown Etiology		
Known history of HF prior to this admission?	O Yes		O No			
# of hospital admissions in past 6 mo. for HF:	00	<b>O</b> 1	O 2	<b>O</b> >2	O Unknown	
Patient Listed for Transplant						
DIAGNOSIS				A	dmission Tab	
Heart Failure Diagnosis	O Heart F	ailure, pr	imary diagno imary diagno econdary diag	sis, no CAD		
Atrial Fibrillation (At presentation or during hospitalization)	O Yes	ON	10	Docume	ented New Onset?	
Atrial Flutter (At presentation or during hospitalization)	O Yes	0	10	Docume	ented New Onset?	
New Diagnosis of Diabetes	O Yes	O N	10	O Not Doc	umented	
Basis for Diagnosis	<ul><li>HbA1c</li><li>Oral Gluc</li></ul>				ng Blood Sugar Other	
Characterization of HF at admission or when first recognized	<ul> <li>Acute Pulr</li> <li>Dizziness/</li> <li>Dyspnea</li> <li>ICD Shock</li> <li>Ventricular</li> </ul>	Syncope /Sustaine	ed	<ul> <li>Pulmonary</li> <li>Volume ov</li> <li>Worsening</li> <li>Other</li> </ul>	/erload/Weight Gain	
Other Conditions Contributing to HF Exacerbation Select all that apply	<ul> <li>Arrhythmia</li> <li>Pneumonia</li> <li>Noncomplia</li> </ul>			<ul> <li>Worsening Renal Failure</li> <li>Ischemia/ACS</li> <li>Uncontrolled HTN</li> <li>Noncompliance – Dietary</li> <li>Other</li> </ul>		
Active bacterial or viral infection at admission or during hospitalization	<ul><li>O Influenza</li><li>O Seasonal C</li></ul>	nfectious COV-1 COV-2 (C nfectious old		athogen		
New Diagnosis of ATTR-CM	<ul> <li>Other Viral Infection</li> <li>Yes</li> <li>Hereditary</li> <li>Wild-Type</li> <li>Unknown/Not Documented</li> <li>No</li> <li>Not Documented</li> </ul>					
MEDICATIONS AT ADMISSION				Admiss	sion Tab	
Medications Used Prior to Admission: [Select						
<ul> <li>Patient on no meds prior to admission</li> <li>ACE Inhibitor</li> <li>Angiotensin receptor blocker (ARB)</li> <li>Angiotensin Receptor Neprilysin Inhibitor (AF</li> <li>Antiarrhythmic</li> <li>Anticoagulation Therapy         <ul> <li>Warfarin</li> <li>Direct Thrombin Inhibitor</li> <li>Factor Xa Inhibitor</li> </ul> </li> </ul>	RNI) As Ca Ca Ca Ca Ca Dig Diu O	pirin ta-Blocko channel ❑ Othe oxin retic	l blocker	ng aspirin) ubcutaneous a	gents	
NOT FOR USE WITHOUT PERMISSION. ©2022 American He	art Association and	QVIA. For	questions, call	888-526-6700		

NOT FOR USE WITHOUT PERMISSION. ©2022 American Heart Association

December 2022

<ul> <li>Other</li> <li>Anti-hyperglycemic medications:         <ul> <li>DPP-4 Inhibitors</li> <li>GLP-1 receptor agonist</li> <li>Insulin</li> <li>Mavacamten</li> <li>Metformin</li> <li>Mineralocorticoid Receptor Antagonist (MRA)</li> <li>Sulfonylurea</li> <li>Thiazolidinedione</li> <li>Other Oral Agents</li> <li>Other injectable/subcutaneous agents</li> </ul> </li> </ul>					<ul> <li>Hydralazine</li> <li>Ivabradine</li> <li>Lipid lowering agent (Any)         <ul> <li>Statin</li> <li>Other Lipid lowering agent</li> </ul> </li> <li>Nitrate</li> <li>Omega-3 fatty acid supplement</li> <li>Renin Inhibitor</li> <li>SGLT2 Inhibitor</li> <li>Vericiguat</li> <li>Other Medications Prior to Admission</li> </ul>					
Symptoms (Clos Admission) Sele apply		O 0	rthopnea 🤇	D Dys D Fati D PNE	gue	at re	st		n Exertion appetite/early satiety ghtheadedness/syncope	
EXAMS/LABS	AT ADMIS		1						Admission Tab	
Height				(	) inc	hes	O cm		O Height ND	
Weight				(	OLbs		OKgs.		O Weight ND	
Waist Circumference				(	) inc	hes	O cm		O Waist Circumference	
BMI							(Automati	cally Calculated		
Systolic							(	,	,	
Diastolic										
O BP ND										
Respiratory Rate (breaths per minute)										
JVP (cm):	O Yes	O No	O Unknown	JVP	Valu	е				
Rales:	O Yes	O No	O Unknown					O <1/3 ≥1/	O N/A	
Lower Extremity Edema	O Yes	O No	O Unknown			tremi	ity Value	O Trace O 1+ O 2+ O 3+ O 4+ O N/A		
l in ide	TC:		HDL:	LD				TG:	🗖 Linida Nat Availabla	
Lipids Labs (Closet to	mg/dL Admissior	n)	mg/dL	ing	/dL			mg/dL	Lipids Not Available	
Sodium (Na+)	, (011100101	'/		O m	Eq/L		O mmol/L	O mg/dL	Not Available	
Hgb				O g/			O g/L	- mg/dL	Not Available	
Albumin				Og/			Og/L		Not Available	
BNP				-	g/mL		O pmol/L	O ng/L	Not Available	
NT-proBNP					g/mL		O ng/L	- · · · <del>9</del> / –	□ Not Available	
Serum Creatinine					g/n∟ ng/dL		O µmol/L		Not Available	
BUN				Qm	ig/dL		O µmol/L		Not Available	
Troponin (Peak)	Ong/mL	Oug			ns-I		O Normal O Abnorma		Not Available	

OT FOR USE WITH		ON. ©2022 American He	art Associ	ation		December 2022						
<b>Potassium</b> (K+) Ferritin			O mE	Eq/L	O mm	nol/L	O mg/o	JL	Not Available			
ng/mL)												
IbA1C		%			□ Not Available							
asting Blood Slucose mg/dL)					🗆 Not	Availa	ble					
KG QRS												
Ouration (ms)	<u></u>											
KG QRS Iorphology	O Normal O LBBB			O RBI					Paced lot Available			
CLINICAL COD				9110	1100			91	Clinical Codes Tab			
CD-10-CM Prir		osis Code										
	<u> </u>		1.			2.			3.			
			4.			5.			6.			
CD-10-CM Oth	er Diagnoses	Codes	7.			8.			9			
						0. 11.			9 12.			
	nainal Draca	dura Cada	10.				1 1					
CD-10-PCS Pri						Date:						
			1.			Date:						
			2. 3.			Date:			O Date UTD			
CD-10-PCS Ot	her Principal	cipal Procedure Codes				Date: _/_/			O Date UTD			
						Date:			O Date UTD			
			5. Da			Date:	//		O Date UTD			
N-HOSPITAL									In-Hospital Tab			
In-Hospital Ca	re											
								Surge	ry			
<ul> <li>No Procedures</li> <li>Cardiac Cath/Coronary Angiography</li> <li>CardioMEMs (implantable hemodynamic monitor)</li> <li>Coronary Artery Bypass Graft</li> <li>CRT-P (cardiac resynchronization therapy-pacing only)</li> <li>Dialysis or Ultrafiltration unspecified</li> <li>ICD only</li> <li>Mechanical Ventilation</li> <li>PCI</li> <li>Right Cardiac Catheterization</li> <li>TMVR</li> <li>Tricuspid Valve Procedure</li> <li>Atrial Fibrillation Ablation of Cardiac Valve Surgery</li> <li>Cardioversion</li> <li>CRT-D (cardiac resynchronization therapy-pacing only)</li> <li>Dialysis or Ultrafiltration unspecified</li> <li>ICD only</li> <li>Mechanical Ventilation</li> <li>PCI</li> <li>Tircuspid Valve Procedure</li> <li>Atrial Fibrillation Ablation of Cardiac Valve Surgery</li> <li>Cardioversion</li> <li>CRT-D (cardiac resynchronization therapy-pacing only)</li> <li>Intra-aortic Balloon Pump</li> <li>Left Ventricular Assist Devi</li> <li>Pacemaker</li> <li>PCI with stent</li> <li>Stress Testing</li> <li>TAVR</li> <li>Transplant (Heart)</li> <li>Ultrafiltration</li> </ul>						synchron Pump	ce	therapy with ICD				
EF - Quantitativ	ve		%			Obta	ined:	O Wit	thin the last year year ago			
F - Qualitative		<ul> <li>Not Applicable</li> <li>Normal or mild dysfunction</li> <li>Qualitative moderate/severe dys</li> <li>Performed/results not available</li> <li>Planned after discharge</li> <li>Not performed</li> <li>Not applicable</li> </ul>			unction	Obta	lined:	O Wit	s Admission hin the last year year ago			
/litral Valve Reo MR) on echoca		O None O Trace/trivial										

### NOT FOR USE WITHOUT PERMISSION. ©2022 American Heart Association

	O 2+ or Moderate							
		<ul> <li>3+ or Moderate to Severe</li> <li>4+ or Severe</li> </ul>						
Documented LVSD?	O Yes		0 N	O No				
LVF Assessment?	O Yes	O No	O Not o	done, Reason Documented				
Oral Medications during hospitalization Select all that apply	<ul><li>None</li><li>ARNI</li><li>ARB</li></ul>	Mineralo	ine Nitrate corticoid · Antagonist	<ul> <li>ACE Inhibitor</li> <li>Beta Blocker</li> <li>SGLT2 Inhibitor</li> </ul>				
IV Iron	Yes	□ No		Not documented				
Parenteral Therapies during hospitalization Select all that apply	<ul> <li>None</li> <li>Dopamine</li> <li>Dobutamine</li> <li>Iron</li> </ul>	<ul> <li>Intermitte</li> <li>Milrinone</li> <li>Nesiritide</li> <li>Other IV</li> <li>Vasopres</li> </ul>	us Infusion ent bolus e Nitroglycerine Vasodilator ssin antagonist					
	ing at the end of hospital da	-	O No	O Not Documented				
Was DVT prophylaxis ir 2?	tiated by the end of hospital	J Yes	O No/Not Documented	O Contraindicated				
DVT prophylaxis type	<ul> <li>Low dose unfracti (LDUH)</li> <li>Low molecular we (LMWH)</li> <li>Warfarin</li> <li>Other</li> </ul>		<ul><li>Direct</li><li>Venou</li><li>Interm</li></ul>	<ul> <li>Direct thrombin inhibitor</li> <li>Venous foot pumps (VFP)</li> </ul>				
Was DVT or PE (pulmor	ary embolus) documented?	O Yes	O No/Not Doc	cumented				
Influenza Vaccination		s received prior to ation tient's refusal of inf influenza or if medi	admission durin luenza vaccine cally contraindio	during the current flu season ng the current flu season, not cated				
COVID-19 Vaccination	O COVID-19 vaccine w	vas given during thi vas received prior to atient's refusal of Co COVID-19 or if me e	s hospitalizatior o admission, no OVID-19 vaccin dically contrain	et during this hospitalization				
COVID-19 Date	//////	/						
Is there documentation the this patient was included a COVID-19 vaccine trial	at O Yes in O No/ND							
Pneumococcal Vaccination	<ul> <li>O Pneumococcal vaccin</li> <li>O Pneumococcal vaccin</li> <li>O Documentation of pati</li> <li>O Allergy/sensitivity or if</li> <li>O None of the above/No</li> </ul>	e was received in t ient's refusal of pne medically contrain	he past, not dur eumococcal vac dicated to pneu	ring this hospitalization				
DISCHARGE INFORMAT	ON			Discharge Tab				
What was the patient's discharge disposition on the day of discharge?	<ul> <li>1 – Home</li> <li>2 – Hospice – Home</li> <li>3 – Hospice – Health Carl</li> <li>4 – Acute Care Facility</li> <li>5 – Other Health Care Facility</li> </ul>	acility	0 0	6 – Expired 7 – Left Against Medical Advice/AMA 8 – Not documented or Unable to Determine (UTD)				
If other Health Care Facility:	<ul> <li>O Skilled Nursing Facility (S</li> <li>O Inpatient Rehabilitation Facility</li> </ul>	,	O Inte O Oth	ermediate Care Facility (ICF) er				

December 2022

#### NOT FOR USE WITHOUT PERMISSION. ©2022 American Heart Association

	O Long Terr	n Care Hospital (LTC	iΗ)							
Skilled Nursing Facility	ND			I.						
If Home, special discharge circumstances:	O Home Hea O Homeless		<ul><li>O Interna</li><li>O Prison</li></ul>	ational /Incarcerate	əd	• None/UTD				
Primary Cause of Death	O Cardiovas	cular	O Non-C	Cardiovascu	lar	O Unknown				
If Cardiovascular:	O Acute Cor	onary Syndrome	O Worse	O Worsening Heart Failure				<ul><li>Sudden Death</li><li>Other</li></ul>		
When is the earliest						unclear				
comfort measures only?				or after		O No	t Doo	cumented		
Symptoms (closest to discharge)	<ul><li>O Worse</li><li>O Unchanged</li></ul>			, Symptoma , Asymptom		O Una	ble to	o determine		
	Weight	O Lbs.	O Kgs.			O No	t Doc	cumented		
Vital Signs (closest to Discharge)	Heart Rate (bpm)					O No	t Doc	umented		
to Discharge)	Systolic					O No	t Doc	umented		
	Diastolic									
	JVP:	O Yes	O No	O Unki	nown	If Yes	s,	cm		
Exam (Closest to	Rales:	O Yes O No	O Unknown	lf Yes,	<b>O</b> <1/3	O ≥1/3		O N/A		
Discharge)	Lower Extremity Edema	O Yes O No	O Unknown	lf Yes,	O Trace O 1+	O 2+ O 3+		O 4+ O N/A		
	Sodium (Na+)		O mEq/L	O mmol/L	Omg	ng/dL 🗖 U		navailable		
	BNP		O pg/mL	O pmol/L O n		μ/L □Ur		navailable		
	Serum Creatinine			O mg/dL	Οµm	O µmol/L □		navailable		
	BUN			O mg/dL	Οµm	nol/L	ΟU	navailable		
	eGFR (mL/min) NT-proBNP (pg/mL)				🗆 No	t Docur	nente	ed		
Labs (Closest to	Potassium (K+)		O mEq/L	O mmol/L	O mg	O mg/dL		Inavailable		
Discharge)	Urinary Albumin (mg/dL)									
	Urinary Creatinine (mg/dL)									
	Urinary Albumin-to- Creatinine Ratio (UACR) (mg/g)									
	Ferritin (mg/mL)		🗅 Unavailabl	le						
DISCHARGE MEDICA	ATIONS					Di	scha	rge Tab		

December 2022

### NOT FOR USE WITHOUT PERMISSION. ©2022 American Heart Association

O Yes O No O NC (None-Contraindicated) ACE Prescribed? ACE Medication/Dosage/Frequency Medication: Dosage: Frequency: Contraindicated Hypotensive patient who was at immediate risk of cardiogenic shock Hospitalized patient who experienced marked azotemia **Contraindications or Other** Other Contraindications **Documented Reason(s) For Not** Not Eligible **Providing ACEI:** Not Tolerant Patient Enrolled in Clinical Trial Patient Reason Svstem Reason Other Reason **ARB Prescribed?** O Yes O No O NC (None-Contraindicated) ARB Medication/ Dosage/Frequency Medication: Dosage: Frequency: Contraindicated Hypotensive patient who was at immediate risk of cardiogenic shock Hospitalized patient who experienced marked azotemia Other Contraindications **Contraindications or Other** Not Eligible **Documented Reason(s) For Not** □ Not Tolerant **Providing ARB:** Patient Enrolled in Clinical Trial Patient Reason System Reason Other Reasons O Yes O No O NC (None-Contraindicated) **ARNI Prescribed?** ARNI Medication/Dosage/Frequency Medication: Dosage: Frequency: Contraindicated □ ACE inhibitor use within the prior 36 hours □ Allergy Hyperkalemia Hypotension □ Renal dysfunction defined as creatinine > 2.5 mg/dL in men or > 2.0 Contraindications or Other Documented ma/dL in women Reason(s) for Not Providing ARNI at Other Contraindications **Discharge:** Not Eligible Not Tolerant Patient Enrolled in Clinical Trial Patient Reason System Reason Other Reasons Reasons for not switching to ARNI at O Yes O ARNI was prescribed at discharge O No discharge: O NYHA Class I If Yes, O NYHA Class IV **Beta Blocker Prescribed?** O Yes O No O NC (None-Contraindicated) O Evidence-Based Beta Blocker O Non-Evidence-Based Beta Blocker Beta Blocker Class O Unknown Class

December 2022

### NOT FOR USE WITHOUT PERMISSION. ©2022 American Heart Association

December 2022

Contraindications or Other Documented Reason(s) For Not Providing Beta Blockers:	<ul> <li>Contraindicated</li> <li>Asthma</li> <li>Fluid Overload</li> <li>Low Blood Pressure</li> <li>Patient recently treated with an intravenous positive inotropic agent</li> <li>Other Contraindications</li> <li>Not Eligible</li> <li>Not Tolerant</li> <li>Patient Enrolled in Clinical Trial</li> <li>Patient Reason</li> <li>System Reason</li> </ul>							
Beta Blocker Medication/Dosage/Frequency	Medication:	Dosage:	Frequency:					
SGLT2 Inhibitor Prescribed?	O Yes O No O NC Medication: Dosage: □ Contraindicated □ Patient currently on dialys □ Ketoacidosis		quency:					
Contraindications or Other Documented Reason(s) For Not Providing SGLT2 Inhibitor:	<ul> <li>Ketoacidosis</li> <li>Known hypersensitivity to the medication</li> <li>Type I diabetes (not approved for use in patients with Type I diabetes due to increased risk of ketoacidosis)</li> <li>Other Contraindications</li> <li>Not Eligible</li> <li>Not Tolerant</li> <li>Patient Enrolled in Clinical Trial</li> <li>Patient Reason</li> <li>System Reason</li> <li>Other Reason</li> </ul>							
Mineralocorticoid Receptor Antagonist (MRA) Prescribed?	O Yes O No O NC (None-Contra	indicated)						
MRA Medication/Dosage/Frequency	Medication:	Dosage:	Frequency:					
Was there a dose increase since prior to admission?	O Yes O No/ND							
Potassium ordered or planned after discharge?	O Yes O No/ND							
Renal function test scheduled	O Yes							
Contraindications or Other Documented Reason(s) for Not Providing Mineralocorticoid Receptor Antagonist (MRA) at Discharge	<ul> <li>No/ND</li> <li>Contraindicated         <ul> <li>Allergy due to MRA</li> <li>Hyperkalemia</li> <li>Renal dysfunction defined as mg/dL in women.</li> <li>Other contraindications</li> <li>Not Eligible</li> <li>Not Tolerant</li> <li>Patient Enrolled in Clinical Trial</li> <li>Patient Reason</li> <li>System Reason</li> <li>Other Reason</li> </ul> </li> </ul>	s creatinine >2.5 mg	g/dL in men or >2.0					
Anticoagulation Therapy Prescribed?	O Yes O No O NC (None-Contra	,						
Anticoagulation Therapy Class	Warfarin     Direct Thrombin Inhibitor     Medication:	Factor Xa     Other						
Anticoagulation Contraindication(s):	Contraindicated	Dosage:	Frequency:					
Anticologulation Contraindication(S). NOT FOR USE WITHOUT PERMISSION. ©2022 Americ		ns, call 888-526-6700						
	Page 9 of 12							

### NOT FOR USE WITHOUT PERMISSION. ©2022 American Heart Association

December 2022

	Alleray to or complication	n r/t anticoagulation	therapy (by or					
	Allergy to or complication r/t anticoagulation therapy (hx or current)							
	Risk for bleeding or discontinued due to bleeding							
	Serious side effect to me	edication	C C					
	Terminal illness/Comfort Measures Only							
	Other Contraindications							
	Not Eligible							
	<ul> <li>Not Tolerant</li> <li>Patient Enrolled in Clinical T</li> </ul>	riol						
	Patient Reason	lidi						
	<ul> <li>System Reason</li> </ul>							
	□ Other							
Hydralazine Nitrate Prescribed?	O Yes O No O NC (None-Contra	indicated)						
	Contraindicated							
	Not Eligible							
Contraindications or Other	Not Tolerant	• •						
Documented Reason(s) For Not	Patient Enrolled in Clinical T	rial						
Providing Hydralazine Nitrate:	<ul><li>Patient Reason</li><li>System Reason</li></ul>							
	<ul> <li>Other Reasons</li> </ul>							
Anti-hyperglycemic Prescribed?	O Yes O No O NC							
	Class:	Medication:						
Antihyperglycemic Class/Medication	Class:	Medication:						
	Class:	Medication:						
	Class.	medication.						
ASA Prescribed?	O Yes O No O NC (None-Contra	,						
ASA Medication/Dosage/Frequency	Medication:	Dosage:	Frequency:					
Other Antiplatelets Prescribed?	O Yes O No O NC (None-Contra	indicated)						
Other Antiplatelets	Medication:	Decesa	Fragueney/					
Medication/Dosage/Frequency		Dosage:	Frequency:					
	Γ							
Clopidogrel Prescribed?	O Yes O No O NC							
Clopidogrel Dosage/Frequency	Dosage:	Frequency:						
Ivabradine Prescribed?	O Yes O No O NC							
	Contraindicated							
	Allergy to Ivabradine							
	Patient 100% atrial or ver	ntricular paced						
	Other Contraindications							
	Not Eligible							
	NYHA class I or IV							
Contraindications or Other Documented	<ul><li>Not in sinus rhythm</li><li>New Onset of HF</li></ul>							
Reason(s) For Not Providing Ivabradine:	<ul> <li>Not treated with maximal</li> </ul>	v tolerated dose bet	a blockers or beta					
	blockers contraindicated							
	Not Tolerant							
	Patient Enrolled in Clinical T	rial						
	Patient Reasons							
	System Reasons							
	Other Medical Reasons							

### NOT FOR USE WITHOUT PERMISSION. ©2022 American Heart Association

Lipid Lowering Medication P	rescribed?	O Yes O No	O NC					
		Class:	Medicati	on:	Dosag	e:	F	requency:
Lipid Lowering Class/Medication/Dosage/Freq	uency	Class:	Medicati	-	Dosage	e:	F	Frequency:
		Class:	Medicati	on:	Dosag	e:	F	Frequency:
Omega-3 Prescribed?		O Yes O No						
Other Medications								
<ul> <li>Antiarrhythmic (Discha</li> <li>Amiodarone</li> <li>Dofetilide</li> <li>Sotalol</li> <li>Other antiarrhy</li> </ul>	(Disch Digox Diuret	<ul> <li>(Discharge)</li> <li>Digoxin (Discharge)</li> <li>Diuretic (Discharge)</li> <li>Loop Diuretic</li> <li>Thiazide Diuretic</li> <li>Other Anti-Hyperte</li> <li>Other medications</li> </ul>			scharge) ensive			
OTHER THERAPIES							Disc	charge Tab
ICD Counseling?	O Yes			O No				
Reason for not counseling	O Yes			O No				
Documented Medical Reason(s) for Not Counseling?	ICE Mu cor		Limited Life Expectancy other reasons not eligible for ICD (e.g. EF>35%, new onset HF) Other reasons for not counseling					
ICD Placed or Prescribed?	O Yes		O No	Other re	easons	for not (	counseling	
Reason(s) for Not Placing								
or Prescribing?	O Yes			O No				
Documented Reason(s) for Not Placing or Prescribing ICD Therapy?	□ No the □ Pa	ontraindications ot receiving optim erapy atient Reason vstem Reason	al medical		Any other physician documented reason including AMI in prior 40 days, recent revascularization, recent onset HF			
CRT-D Placed or Prescribed?				O Yes			O No	
CRT-P Placed or Prescribed?	>			O Yes			O No	
Reason for not Placing or Pro	escribing?			O Yes			O No	
Documented Reason(s) for Not Placing or Prescribing CRT Therapy?	No the No or	ontraindications of receiving optim erapy of NYHA function ambulatory Class atient Reason	al Class III		reason recent r HF	Any other physician documented reason including AMI in prior 40 days, recent revascularization, recent onset of HF System Reason		
<b>RISK INTERVENTIONS</b>							Disc	charge Tab
Smoking Cessation Counseling Given	O Yes			0	No			
Smoking Cessation Therapies Prescribed (select all that apply)		eatment Not Spe ounseling Only ver the Counter N eplacement Thera		Prescrip Other	otion M	edicatio	ns	
DISCHARGE INSTRUCTIONS								charge Tab
Activity Level	O Yes	O No	Diet (Salt re	stricted)		O Ye		O No
Follow-up	O Yes	O No	Medications			O Ye		O No
Symptoms Worsening	O Yes	O No	Weight Mon	itoring		O Ye	S	O No

NOT FOR USE WITHOUT PERMISSION. ©2022 American Heart Association

### December 2022

Follow-up Visit Scheduled	O Yes	0	No	Date/Time o up visit:	f first	follow-	//	/			
Location of first follow-up visi	it:	i.		O Office Vis O Home Hea		sit	O Telehe O Not Do	ealth ocumented			
Medical or Patient Reason for appointment being scheduled		v-up		O Yes			O No				
Follow-up Phone Call Scheduled	O Yes	0	No	Date/Time of first follow-up phone call:			/				
Follow-up appointment scheduled for diabetes	O Yes	0	No	Date of diabetes management follow-up visit:			//	//			
management? OTHER RISK INTERVENTIONS				inanagemen		ap nom		Diacharra	Tob		
TLC (Therapeutic Lifestyle Ch		<b>^</b>	O Yes	O No				Discharge			
	ange) Die	ŧ	O Yes			ot Docume	ot Documented O Not Applicable				
Obesity Weight Management								O Not Appli			
Activity Level/Recommendation Referred to Outpatient Cardia	c Pohah		O Yes	O No		ot Docume		O Not Appli	cable		
Program			O Yes	O No		ot Docume		O Not Appli			
Anticoagulation Therapy Educat			O Yes	O No		ot Docume		O Not Appli			
Was Diabetes Teaching provide	d?		O Yes	O No	O No	ot Docume		O Not Appli			
PT/INR Planned Follow-Up			O Yes	O No		ot Docume		O Not Appli			
Referral to Sleep Study			O Yes	O No	O No	ot Docume	ented	O Not Appli	cable		
Referral to Outpatient HF Management Program			O Yes	O No O Not Docume			onted O Not Applicable				
Outpatient HF Management Program Type(s):			Telemanagement D Ho			ome Visit		Clinic-bas	sed		
Referral to AHA My HF Guide/Heart Failure Interactive Workbook			O Yes	O No	No O Not Documented			O Not Applicable			
Provision of at least 60 minute Failure Education by a qualifie			O Yes	O No O Not Documented			ented	O Not Applicable			
Advanced Care Plan/Surrogate Documented Or Discussed?			O Yes	Yes O No O Not Docur			nented O Not Applicable				
Advance Directive Executed			O Yes		O No	C					
POST DISCHARGE TRANSITIO	NC							Discharge	Tab		
Care Transition Record Transmi	itted	O Exis	sts, but not	n post-dischar transmitted by sition Record/U	y the s		st-discharç	ge day			
			were incluc	led (Check all	yes)						
		D	ischarge N	ledications				O Yes	O No		
Care Transition Record Transmi	itted	F	ollow-up T	reatment(s) ar	nd Serv	vice(s) Nee	eded	O Yes	O No		
Includes		Р	rocedures	Performed Du	ring H	ospitalizati	ion	O Yes	O No		
		R	eason for l	Hospitalizatior	1			O Yes	O No		
		T	reatment(s	)/Service(s) P	rovideo	b		O Yes	O No		
During this admission, was a standardized health related socia needs form or assessment comp		O Yes				o No/NE	)				
If yes, identify the areas of un social need. (select all that ap		so D E D F D F	one of the ocial need ducation mploymen inancial St ood iving Situat	train Personal Personal Substance Transpor				al Safety			